Handelsbanken Fonder AB Acquires 140,901 Shares of Bristol Myers Squibb Company $BMY

Handelsbanken Fonder AB grew its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 12.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,269,920 shares of the biopharmaceutical company’s stock after acquiring an additional 140,901 shares during the period. Handelsbanken Fonder AB’s holdings in Bristol Myers Squibb were worth $68,499,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in the business. Northwestern Mutual Investment Management Company LLC lifted its holdings in Bristol Myers Squibb by 0.3% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock valued at $3,509,000 after purchasing an additional 172 shares during the last quarter. ESG Planning DBA Harper Investing raised its position in shares of Bristol Myers Squibb by 1.3% in the fourth quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock valued at $745,000 after purchasing an additional 180 shares during the period. Novem Group raised its position in shares of Bristol Myers Squibb by 2.9% in the fourth quarter. Novem Group now owns 6,402 shares of the biopharmaceutical company’s stock valued at $345,000 after purchasing an additional 183 shares during the period. Dominguez Wealth Management Solutions Inc. raised its position in shares of Bristol Myers Squibb by 0.8% in the fourth quarter. Dominguez Wealth Management Solutions Inc. now owns 22,404 shares of the biopharmaceutical company’s stock valued at $1,208,000 after purchasing an additional 185 shares during the period. Finally, McLean Asset Management Corp raised its position in shares of Bristol Myers Squibb by 3.1% in the fourth quarter. McLean Asset Management Corp now owns 6,465 shares of the biopharmaceutical company’s stock valued at $369,000 after purchasing an additional 192 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Trading Up 0.5%

BMY opened at $57.30 on Tuesday. The company has a market cap of $117.02 billion, a P/E ratio of 16.10, a PEG ratio of 0.16 and a beta of 0.26. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The company’s 50 day moving average is $58.57 and its 200-day moving average is $55.53. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the business posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.31 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.05% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on BMY shares. Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective on the stock. Guggenheim reissued a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Sunday, April 19th. Finally, Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.